Your browser doesn't support javascript.
loading
2019 White Paper on Recent Issues in Bioanalysis: Chromatographic Assays (Part 1 - Innovation in Small Molecules and Oligonucleotides & Mass Spectrometric Method Development Strategies for Large Molecule Bioanalysis).
Fandozzi, Christine; Evans, Christopher; Wilson, Amanda; Su, Dian; Anderson, Melanie; Clausen, Valerie; Dillen, Lieve; Garofolo, Fabio; Holliman, Chris; Nickbarg, Elliott; Olah, Timothy; Ramanathan, Ragu; Zhang, Hui; Kaur, Surinder; Pillutla, Renuka; Yu, Hongbin; Bateman, Kevin; Donato, Lorella Di; Hengel, Shawna; Jian, Wenying; Jones, Barry; Kellie, John; Lee, Anita; Palandra, Joe; Savoie, Natasha; Shipkova, Petia; Spitz, Susan; Su, Dian; Szapacs, Matthew; Wang, Jian; Wright, Katherine; Zeng, Jianing.
Afiliação
  • Fandozzi C; Merck, West Point, PA, USA.
  • Evans C; GlaxoSmithKline, Collegeville, PA, USA.
  • Wilson A; Clinical Pharmacology & Safety Sciences, Translational Biomarker & Bioanalysis, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Su D; Genentech, South San Francisco, CA, USA.
  • Anderson M; Merck, Philadelphia, PA, USA.
  • Clausen V; Alnylam Pharmaceuticals, Cambridge, MA, USA.
  • Dillen L; Janssen Research & Development, Beerse, Belgium.
  • Garofolo F; Angelini Pharma, Pomezia, RM, Italy.
  • Holliman C; Pfizer, Groton, CT, USA.
  • Nickbarg E; Merck, Boston, MA, USA.
  • Olah T; Bristol-Myers Squibb, Princeton, NJ, USA.
  • Ramanathan R; Pfizer, Groton, CT, USA.
  • Zhang H; Pfizer, Groton, CT, USA.
  • Kaur S; Genentech, South San Francisco, CA, USA.
  • Pillutla R; Bristol-Myers Squibb, Princeton, NJ, USA.
  • Yu H; Boehringer-Ingelheim, Ridgefield, CT, USA.
  • Bateman K; Merck, West Point, PA, USA.
  • Donato LD; Caprion, Montreal, QC, Canada.
  • Hengel S; Seattle Genetics, Inc., Bothell, WA, USA.
  • Jian W; Janssen Research & Development, Spring House, PA, USA.
  • Jones B; Q2 Solutions, Ithaca, NY, USA.
  • Kellie J; GlaxoSmithKline, Collegeville, PA, USA.
  • Lee A; Merck, Kenilworth, NJ, USA.
  • Palandra J; Pfizer, Andover, MA, USA.
  • Savoie N; CFABS, Montreal, QC, CAN.
  • Shipkova P; Bristol-Myers Squibb, Princeton, NJ, USA.
  • Spitz S; Incyte, Wilmington, DE, USA.
  • Su D; Genentech, South San Francisco, CA, USA.
  • Szapacs M; GlaxoSmithKline, Collegeville, PA, USA.
  • Wang J; Bristol-Myers Squibb, Princeton, NJ, USA.
  • Wright K; Pfizer, Andover, MA, USA.
  • Zeng J; Bristol-Myers Squibb, Princeton, NJ, USA.
Bioanalysis ; 11(22): 2029-2048, 2019 Nov.
Article em En | MEDLINE | ID: mdl-31808716
The 2019 13th Workshop on Recent Issues in Bioanalysis (WRIB) took place in New Orleans, LA, USA on April 1-5, 2019 with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, week-long event - a full immersion week of bioanalysis, biomarkers, immunogenicity and gene therapy. As usual, it was specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest including both small- and large-molecule bioanalysis involving LCMS, hybrid LBA/LCMS, LBA cell-based/flow cytometry assays and qPCR approaches. This 2019 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2019 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 1) covers the recommendations on Innovation in Small Molecules and Oligonucleotides & Mass Spec Method Development Strategies for Large Molecules Bioanalysis. Part 2 (2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and regulatory agencies' input on bioanalysis, biomarkers, immunogenicity and gene therapy) and Part 3 (New Insights in Biomarkers Assays Validation, Current & Effective Strategies for Critical Reagent Management, Flow Cytometry Validation in drug discovery & development & CLSI H62, Interpretation of the 2019 FDA Immunogenicity Guidance and The Gene Therapy Bioanalytical Challenges) are published in volume 11 of Bioanalysis, issues 23 and 24 (2019), respectively.
Assuntos

Texto completo: 1 Temas: ECOS / Estado_mercado_regulacao Bases de dados: MEDLINE Assunto principal: Oligonucleotídeos / Espectrometria de Massas / Cromatografia Líquida / Bibliotecas de Moléculas Pequenas / Invenções Tipo de estudo: Guideline / Qualitative_research Idioma: En Revista: Bioanalysis Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Temas: ECOS / Estado_mercado_regulacao Bases de dados: MEDLINE Assunto principal: Oligonucleotídeos / Espectrometria de Massas / Cromatografia Líquida / Bibliotecas de Moléculas Pequenas / Invenções Tipo de estudo: Guideline / Qualitative_research Idioma: En Revista: Bioanalysis Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos